New biomarkers on track for commercial launch in January 2025
Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
Read more at globenewswire.comExagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
EXAGEN INC
NASDAQ:XGN (2/11/2025, 2:05:26 PM)
4.73
-0.07 (-1.46%)
XGN Latest News and Analysis
7 days ago - ChartmillTuesday's session: top gainers and losersStay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
